Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer-Reference-Cited by-同舟云学术

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Published:2009-11 Issue:11 Volume:20 Page:1794-1802
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Del Campo J.M.,Roszak A.,Bidzinski M.,Ciuleanu T.E.,Hogberg T.,Wojtukiewicz M.Z.,Poveda A.,Boman K.,Westermann A.M.,Lebedinsky C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/20/11/1794/472578/mdp198.pdf

Reference44 articles.

1. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer;Carter;Drugs,2007

2. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743);Schöffski;Proc Am Soc Clin Oncol,2006

3. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails;Sessa;J Clin Oncol,2005

4. A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens;Krasner;Br J Cancer,2007

5. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer;Carter;Drugs,2007

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DNA Damage Response Alterations in Ovarian Cancer: From Molecular Mechanisms to Therapeutic Opportunities;Cancers;2023-01-10

2. Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26);Gynecologic Oncology;2022-12

3. Trabectedin in Cancers: Mechanisms and Clinical Applications;Current Pharmaceutical Design;2022-07

4. Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study;Clinical Cancer Research;2021-12-29

5. Trabectedin-Related Heart Failure: Case Report and a Systematic Review of the Literature;Frontiers in Oncology;2021-11-18